|
|
|
|
|
Laronidase
drug data and news
Laronidase drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Laronidase | ||
| Brand Names/Synonyms | Alpha-L-iduronidase precursor; Aldurazyme (Biomarin Pharmaceuticals) | ||
| Indication | For treatment of mucopolysaccharidosis | ||
| Sponsored links | Description | Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites. | |
| Pharmacology | Laronidase is used to treat mucopolysaccharide storage disorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-L-iduronidase. Reduced or absent a-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction. | ||
| Mechanism Of Action | Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate. | ||
| Laronidase News (When available) |
BioMarin to Present at Cowen & Co. 26th Annual Health Care ... Feb 27, 2006 BioMarin Announces Fourth Quarter and Year-End 2005 Financial ... Feb 23, 2006 | ||
| Dosage Forms | SOLUTION | ||
| Drug_Category | Enzyme replacement; enzymes (44:00.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Human alpha-L-iduronidase | ||
| Chemical Formula | C3160H4848N898O881S12 | ||
| Molecular Weight | 69899.4 | ||
| Smiles String | Not Available | ||
| Melting Point | Mandelli J, Wajner A, Pires R, Giugliani R, Coelho JC. Detection of mucopolysaccharidosis type I heterozygotes on the basis of the biochemical properties of plasma alpha-L-iduronidase. Clin Chim Acta. 2001 Oct;312(1-2):81-6. | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.3 | ||
| Isoelectric Point | 9.09 | ||
| Biotransformation | Not Available | ||
| Half Life | 1.5-3.6 hrs | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Laronidase.html http://www.rxlist.com/cgi/generic3/aldurazyme.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00008 | ||
| CAS Registry Number | 50378-38-2; 210589-09-6 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10125 | ||
| SwissProt ID | IDUA_HUMAN (P35475) | ||
| GenBank ID | M74715 | ||
| Drug ID Number [DIN] | 2254506 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |